Abstract
We randomized 66 elderly patients with AML unfit for conventional chemotherapy to receive G-CSF from d6 or from d12 after induction-chemotherapy with cytarabine/idarubicin. There was no difference in duration of neutropenia (17 days vs. 19 days, p=0.67) or rate of complications. Delayed treatment can reduce the administration of G-CSF without adverse consequences.
Cite
CITATION STYLE
Von Lilienfeld-Toal, M., Hahn-Ast, C., Kirchner, H., Flieger, D., Dölken, G., & Glasmacher, A. (2007). A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy. Haematologica, 92(12), 1719–1720. https://doi.org/10.3324/haematol.11516
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
